Literature DB >> 14724389

Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma.

Jack Rosenbluth1, Rolf Schiff, Wei-Lan Liang, Wenkai Dou.   

Abstract

We showed previously that spinal cord implants of hybridoma cells (O1) that secrete an IgM antigalactocerebroside cause focal multiple-sclerosis-like plaques of demyelination followed by remyelination to form "shadow plaques" (Rosenbluth et al., 1999). The antibody in that case was directed against a glycolipid present in mature oligodendrocytes and myelin but not in precursor cells. We now report the effects of implanting a different hybridoma (O4) that secretes IgM antibodies directed against sulfatide, a constituent not only of mature myelin and oligodendrocytes but also of late precursor cells, in order to determine whether this hybridoma too would generate focal demyelination and would, in addition, block remyelination. Our results show that focal plaques of demyelination indeed appear after O4 implantation, and that remyelination does occur, but only in cases where the hybridoma cells have degenerated, probably through host rejection. The occurrence of remyelination suggests that oligodendrocyte precursor cells are capable of migrating in rapidly from adjacent areas or that early precursors, not yet expressing sulfatide, remain undamaged within the lesions. In cases where intact hybridoma cells persist at lesion sites, remyelination does not occur. Failure of remyelination in this model thus appears to result from the continuing presence of antimyelin antibodies rather than from depletion of oligodendrocyte precursors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14724389     DOI: 10.1023/B:NEUR.0000010085.91976.a6

Source DB:  PubMed          Journal:  J Neurocytol        ISSN: 0300-4864


  9 in total

1.  Inflammation and remyelination in the central nervous system: a tale of two systems.

Authors:  Francesca Ruffini; Timothy E Kennedy; Jack P Antel
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

2.  An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis.

Authors:  Francesco Lolli; Barbara Mulinacci; Alfonso Carotenuto; Bruno Bonetti; Giuseppina Sabatino; Benedetta Mazzanti; Anna Maria D'Ursi; Ettore Novellino; Marta Pazzagli; Laura Lovato; Maria C Alcaro; Elisa Peroni; Maria C Pozo-Carrero; Francesca Nuti; Luca Battistini; Giovanna Borsellino; Mario Chelli; Paolo Rovero; Anna Maria Papini
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

3.  Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis.

Authors:  Kathryn M Brennan; Francesc Galban-Horcajo; Simon Rinaldi; Colin P O'Leary; Carl S Goodyear; Gabriela Kalna; Ariel Arthur; Christina Elliot; Sue Barnett; Christopher Linington; Jeffrey L Bennett; Gregory P Owens; Hugh J Willison
Journal:  J Neuroimmunol       Date:  2011-08-26       Impact factor: 3.478

4.  Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice.

Authors:  Krishnakumar Menon; Yanghong Wu; Joel Haas; Shailendra K Sahu; Baoli Yang; Asgar Zaheer
Journal:  Neurosci Res       Date:  2007-02-22       Impact factor: 3.304

5.  Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

Authors:  Luisa M Villar; María C Sádaba; Ernesto Roldán; Jaime Masjuan; Pedro González-Porqué; Noelia Villarrubia; Mercedes Espiño; José A García-Trujillo; Alfredo Bootello; José C Alvarez-Cermeño
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

6.  Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation.

Authors:  Peggy P Ho; Jennifer L Kanter; Amanda M Johnson; Hrishikesh K Srinagesh; Eun-Ju Chang; Timothy M Purdy; Keith van Haren; William R Wikoff; Tobias Kind; Mohsen Khademi; Laura Y Matloff; Sirisha Narayana; Eun Mi Hur; Tamsin M Lindstrom; Zhigang He; Oliver Fiehn; Tomas Olsson; Xianlin Han; May H Han; Lawrence Steinman; William H Robinson
Journal:  Sci Transl Med       Date:  2012-06-06       Impact factor: 17.956

7.  Proteomic strategies in multiple sclerosis and its animal models.

Authors:  Stella Elkabes; Hong Li
Journal:  Proteomics Clin Appl       Date:  2007-10-16       Impact factor: 3.494

8.  Differential binding patterns of anti-sulfatide antibodies to glial membranes.

Authors:  Gavin R Meehan; Rhona McGonigal; Madeleine E Cunningham; Yuzhong Wang; Jennifer A Barrie; Susan K Halstead; Dawn Gourlay; Denggao Yao; Hugh J Willison
Journal:  J Neuroimmunol       Date:  2018-07-09       Impact factor: 3.478

9.  Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis.

Authors:  Lorna Hayden; Tiia Semenoff; Verena Schultz; Simon F Merz; Katie J Chapple; Moses Rodriguez; Arthur E Warrington; Xiaohong Shi; Clive S McKimmie; Julia M Edgar; Katja Thümmler; Chris Linington; Marieke Pingen
Journal:  Acta Neuropathol Commun       Date:  2020-08-13       Impact factor: 7.801

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.